These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 36145406)
1. LBMPL Vaccine Therapy Induces Progressive Organization of the Spleen Microarchitecture, Improved Th1 Adaptative Immune Response and Control of Parasitism in Roatt BM; de Oliveira Cardoso JM; Reis LES; Moreira GJL; Gonçalves LC; de Souza Marques F; das Dores Moreira N; de Abreu Vieira PM; de Oliveira Aguiar-Soares RD; Giunchetti RC; Reis AB Pathogens; 2022 Aug; 11(9):. PubMed ID: 36145406 [TBL] [Abstract][Full Text] [Related]
2. Down regulation of IL-10 and TGF-β1 mRNA expression associated with reduced inflammatory process correlates with control of parasitism in the liver after treatingL. infantuminfected dogs with the LBMPL vaccine therapy. Mendes Roatt B; Mirelle de Oliveira Cardoso J; Cristiane Fortes de Brito R; Eduardo Soares Reis L; José Lucas Moreira G; Melo de Abreu Vieira P; Marques de Souza F; Geraldo de Lima W; Dian de Oliveira Aguiar-Soares R; Cordeiro Giunchetti R; Barbosa Reis A Cytokine; 2022 May; 153():155838. PubMed ID: 35259630 [TBL] [Abstract][Full Text] [Related]
3. A Vaccine Therapy for Canine Visceral Leishmaniasis Promoted Significant Improvement of Clinical and Immune Status with Reduction in Parasite Burden. Roatt BM; Aguiar-Soares RD; Reis LE; Cardoso JM; Mathias FA; de Brito RC; da Silva SM; Gontijo NF; Ferreira SA; Valenzuela JG; Corrêa-Oliveira R; Giunchetti RC; Reis AB Front Immunol; 2017; 8():217. PubMed ID: 28321217 [TBL] [Abstract][Full Text] [Related]
5. Immunochemotherapy for visceral leishmaniasis: combinatorial action of Miltefosine plus LBSapMPL vaccine improves adaptative Th1 immune response with control of splenic parasitism in experimental hamster model. Carvalho LM; Gusmão MR; Costa AFP; de Brito RCF; Aguiar-Soares RDO; Cardoso JMO; Reis AB; Carneiro CM; Roatt BM Parasitology; 2022 Mar; 149(3):371-379. PubMed ID: 35264268 [TBL] [Abstract][Full Text] [Related]
6. Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial. Lemesre JL; Holzmuller P; Gonçalves RB; Bourdoiseau G; Hugnet C; Cavaleyra M; Papierok G Vaccine; 2007 May; 25(21):4223-34. PubMed ID: 17395339 [TBL] [Abstract][Full Text] [Related]
7. A Leishmania-specific hypothetical protein expressed in both promastigote and amastigote stages of Leishmania infantum employed for the serodiagnosis of, and as a vaccine candidate against, visceral leishmaniasis. Martins VT; Duarte MC; Chávez-Fumagalli MA; Menezes-Souza D; Coelho CS; de Magalhães-Soares DF; Fernandes AP; Soto M; Tavares CA; Coelho EA Parasit Vectors; 2015 Jul; 8():363. PubMed ID: 26160291 [TBL] [Abstract][Full Text] [Related]
8. Immunization of Experimental Dogs With Salivary Proteins From Abbehusen MMC; Cunha J; Suarez MS; Teixeira C; Almeida VDA; Pereira LDS; Bordoni M; Gil-Santana L; Solcà MDS; Fraga DBM; Fischer L; Bozza PT; Veras PST; Valenzuela JG; Kamhawi S; Andrade BB; Brodskyn CI Front Immunol; 2018; 9():2558. PubMed ID: 30519235 [TBL] [Abstract][Full Text] [Related]
9. Impact of LbSapSal Vaccine in Canine Immunological and Parasitological Features before and after Leishmania chagasi-Challenge. Resende LA; Aguiar-Soares RD; Gama-Ker H; Roatt BM; Mendonça LZ; Alves ML; Silveira-Lemos Dd; Corrêa-Oliveira R; Martins-Filho OA; Araújo MS; Fujiwara RT; Gontijo NF; Reis AB; Giunchetti RC PLoS One; 2016; 11(8):e0161169. PubMed ID: 27556586 [TBL] [Abstract][Full Text] [Related]
10. Systemic and compartmentalized immune response in canine visceral leishmaniasis. Reis AB; Martins-Filho OA; Teixeira-Carvalho A; Giunchetti RC; Carneiro CM; Mayrink W; Tafuri WL; Corrêa-Oliveira R Vet Immunol Immunopathol; 2009 Mar; 128(1-3):87-95. PubMed ID: 19054576 [TBL] [Abstract][Full Text] [Related]
11. Interleukin-12 augments a Th1-type immune response manifested as lymphocyte proliferation and interferon gamma production in Leishmania infantum-infected dogs. Strauss-Ayali D; Baneth G; Shor S; Okano F; Jaffe CL Int J Parasitol; 2005 Jan; 35(1):63-73. PubMed ID: 15619517 [TBL] [Abstract][Full Text] [Related]
12. Leishmania infantum transfected with toxic plasmid induces protection in mice infected with wild type L. infantum or L. amazonensis. Zorgi NE; Arruda LV; Paladine I; Roque GAS; Araújo TF; Brocchi M; Barral M; Sanchiz Á; Requena JM; Abánades DR; Giorgio S Mol Immunol; 2020 Nov; 127():95-106. PubMed ID: 32949849 [TBL] [Abstract][Full Text] [Related]
13. Recovery of antigen-specific T cell responses from dogs infected with Leishmania (L.) infantum by use of vaccine associated TLR-agonist adjuvant. Schaut RG; Grinnage-Pulley TL; Esch KJ; Toepp AJ; Duthie MS; Howard RF; Reed SG; Petersen CA Vaccine; 2016 Oct; 34(44):5225-5234. PubMed ID: 27665354 [TBL] [Abstract][Full Text] [Related]
14. Allopurinol therapy provides long term clinical improvement, but additional immunotherapy is required for sustained parasite clearance, in Nascimento LFM; Miranda DFH; Moura LD; Pinho FA; Werneck GL; Khouri R; Reed SG; Duthie MS; Barral A; Barral-Netto M; Cruz MSP Vaccine X; 2020 Apr; 4():100048. PubMed ID: 31891152 [TBL] [Abstract][Full Text] [Related]
15. Therapeutic vaccine of killed Leishmania amazonensis plus saponin reduced parasite burden in dogs naturally infected with Leishmania infantum. Viana KF; Lacerda G; Teixeira NS; Rodrigues Cangussu AS; Sousa Aguiar RW; Giunchetti RC Vet Parasitol; 2018 Apr; 254():98-104. PubMed ID: 29657019 [TBL] [Abstract][Full Text] [Related]
16. Use of a recombinant cysteine proteinase from Leishmania (Leishmania) infantum chagasi for the Immunotherapy of canine visceral Leishmaniasis. Ferreira JH; Silva Ldos S; Longo-Maugéri IM; Katz S; Barbiéri CL PLoS Negl Trop Dis; 2014 Mar; 8(3):e2729. PubMed ID: 24625516 [TBL] [Abstract][Full Text] [Related]
17. Performance of LBSap vaccine after intradermal challenge with L. infantum and saliva of Lu. longipalpis: immunogenicity and parasitological evaluation. Roatt BM; Aguiar-Soares RD; Vitoriano-Souza J; Coura-Vital W; Braga SL; Corrêa-Oliveira R; Martins-Filho OA; Teixeira-Carvalho A; de Lana M; Figueiredo Gontijo N; Marques MJ; Giunchetti RC; Reis AB PLoS One; 2012; 7(11):e49780. PubMed ID: 23189161 [TBL] [Abstract][Full Text] [Related]
18. Multicomponent LBSap vaccine displays immunological and parasitological profiles similar to those of Leish-Tec® and Leishmune® vaccines against visceral leishmaniasis. de Mendonça LZ; Resende LA; Lanna MF; Aguiar-Soares RD; Roatt BM; Castro RA; Batista MA; Silveira-Lemos D; Gomes Jde A; Fujiwara RT; Rezende SA; Martins-Filho OA; Corrêa-Oliveira R; Dutra WO; Reis AB; Giunchetti RC Parasit Vectors; 2016 Aug; 9(1):472. PubMed ID: 27577735 [TBL] [Abstract][Full Text] [Related]
19. A chimeric vaccine combined with adjuvant system induces immunogenicity and protection against visceral leishmaniasis in BALB/c mice. Ostolin TLVDP; Gusmão MR; Mathias FAS; Cardoso JMO; Roatt BM; Aguiar-Soares RDO; Ruiz JC; Resende DM; de Brito RCF; Reis AB Vaccine; 2021 May; 39(20):2755-2763. PubMed ID: 33875268 [TBL] [Abstract][Full Text] [Related]